Literature DB >> 9174609

Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon-gamma-modulated proteasome subunits.

R Stohwasser1, S Standera, I Peters, P M Kloetzel, M Groettrup.   

Abstract

The primary structures of the interferon-gamma-inducible mouse 20S proteasome subunit MECL-1 and its alternate homolog MC14 were determined. Northern analysis of mouse tissues revealed that MECL-1 mRNA predominantly occurred in thymus, lymph nodes, and spleen, whereas small amounts were detected in non-lymphoid tissues such as kidney, muscle, and testis. Unexpectedly, probing RNA blots with MC14 showed that tissues with high MECL-1 expression contained little MC14 and vice versa. A very similar reciprocal tissue expression was subsequently found for the homologous subunit pairs LMP2 and delta as well as LMP7 and MB1. The subunit protein composition of 20S proteasomes purified from liver, thymus, and lung reflected RNA expression. The impact of a regulated reciprocal tissue expression is discussed with respect to thymic selection and the induction of tolerance in potentially autoreactive T cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174609     DOI: 10.1002/eji.1830270520

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor beta subunits.

Authors:  D Nandi; E Woodward; D B Ginsburg; J J Monaco
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

Review 2.  Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.

Authors:  Nathalie Vigneron; Benoît J Van den Eynde
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

3.  Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.

Authors:  Kimberly Cornish Carmony; Lalit Kumar Sharma; Do-Min Lee; Ji Eun Park; Wooin Lee; Kyung-Bo Kim
Journal:  Chembiochem       Date:  2014-12-04       Impact factor: 3.164

4.  Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer.

Authors:  Fulvia Cerruti; Marina Martano; Claudio Petterino; Enrico Bollo; Emanuela Morello; Renato Bruno; Paolo Buracco; Paolo Cascio
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

5.  A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction.

Authors:  Selina Khan; Albert Zimmermann; Michael Basler; Marcus Groettrup; Hartmut Hengel
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 6.  The role of the proteasome in the generation of MHC class I ligands and immune responses.

Authors:  E J A M Sijts; P M Kloetzel
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

7.  Mice completely lacking immunoproteasomes show major changes in antigen presentation.

Authors:  Eleanor Z Kincaid; Jenny W Che; Ian York; Hernando Escobar; Eduardo Reyes-Vargas; Julio C Delgado; Raymond M Welsh; Margaret L Karow; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Kenneth L Rock
Journal:  Nat Immunol       Date:  2011-12-25       Impact factor: 25.606

8.  Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits.

Authors:  T A Griffin; D Nandi; M Cruz; H J Fehling; L V Kaer; J J Monaco; R A Colbert
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

Review 9.  A novel proteasome inhibitor NPI-0052 as an anticancer therapy.

Authors:  D Chauhan; T Hideshima; K C Anderson
Journal:  Br J Cancer       Date:  2006-10-23       Impact factor: 7.640

Review 10.  The role of major histocompatibility complex molecules in luteal function.

Authors:  Matthew J Cannon; Joy L Pate
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.